{"success":true,"data":{"pressRelease":{"id":"159305","rtpr_id":"nGNEb8dFgf-20261002","ticker":"TEVA","exchange":"","all_tickers":["TEVA"],"title":"Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients","author":"Globe Newswire","published_at":"2026-10-02T12:00:00.132Z","article_body":"* The published review examines dopamine’s role in tic generation and how\napproved and investigational drugs may affect dopamine to reduce tics as well\nas synthesizes clinical trial evidence that ecopipam reduces tic severity,\nprovides sustained benefit over time and helps prevent relapse without some of\nthe complications associated with antipsychotic agents.¹\n* Ecopipam is an investigational, selective D1 (dopamine) receptor antagonist\ntargeting dopaminergic signaling in the brain’s direct motor pathway\nimplicated in Tourette syndrome.\n* Unlike D2 antipsychotics that target D2 receptors in the indirect pathway,\necopipam selectively targets D1 receptors in the direct motor pathway,\noffering a differentiated approach that may reduce tic severity while\npotentially avoiding common adverse events associated with D2-targeting\ntherapies.(1)\nPARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a\nU.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),\ntoday announced that the Journal of Child Neurology published a comprehensive\nreview examining dopamine pathways in Tourette syndrome and the therapeutic\npotential of ecopipam, a first-in-class investigational selective D1\n(dopamine) receptor antagonist for the treatment of pediatric patients with\nTourette syndrome.(1,2) The review evaluates current treatment limitations and\ndetails how selectively targeting D1 receptors in the brain’s direct motor\npathway may offer a differentiated, non-antipsychotic approach for managing\ntics in pediatric patients.(1)\n\n“Tourette syndrome affects up to 1 in 130 children globally and can have a\nprofound impact on a child's daily life, education and social development,”\nsaid Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief\nMedical Officer at Teva. “The review published in the Journal of Child\nNeurology reinforces the potential of ecopipam’s selective dopamine D1\nreceptor approach. This is the kind of innovative programs we are pursuing at\nTeva—advancing differentiated science to address meaningful unmet needs.”\n\nThe comprehensive review details the neurobiological rationale for D1 receptor\nantagonism compared with existing therapies. In Tourette syndrome, elevated\ndopaminergic activity in the basal ganglia is proposed to contribute to the\nexpression of involuntary tics. Because D1 receptors are primarily expressed\nby neurons in the direct motor pathway, ecopipam is hypothesized to block\nexcess dopaminergic activity in this pathway, thereby normalizing downstream\nbasal ganglia signaling and movement patterns. In contrast, traditional\nantipsychotics target D2 receptors, which are primarily associated with the\nindirect pathway.\n\nThis mechanistic distinction is supported by clinical data synthesized across\nthe ecopipam development program. In a Phase 3 trial (n=216, including 167\npediatric), continued ecopipam treatment cut the risk of tic relapse by 50%\nversus placebo in pediatric participants (HR: 0.5; P=0.008), building on Phase\n2b and 12-month open-label data showing sustained reductions in tic severity.\nAcross clinical trials, the most common adverse events included somnolence,\nheadache, insomnia, fatigue and anxiety while ecopipam was not associated with\nclinically relevant weight gain, adverse metabolic effects or drug-induced\nmovement disorders. The potential importance of this efficacy and tolerability\nprofile is underscored by real-world treatment persistence data, which show\nthat treatment discontinuation rates among patients newly treated with D2\nreceptor antagonists were 61.2% by 3 months and 82.1% by 18 months.(1)\n\n“Treatment of Tourette syndrome can be complex, as clinicians must balance\ntic improvement with the side effect profiles of current therapies,” said\nDonald L. Gilbert, M.D., M.S., senior author of the review and Pediatric\nMovement Disorders and Tourette Syndrome Specialist, Division of Neurology,\nCincinnati Children’s Hospital Medical Center. “Ecopipam selectively\ntargets the dopamine D1 receptor, and the data reviewed in this publication\n– demonstrating reduced tic severity and sustained benefit without\nsignificant weight gain, metabolic complications or movement disorders –\nsupports continued research into D1 receptor antagonism for Tourette\nsyndrome.”\n\nFor more information on the review published online in the Journal of Child\nNeurology, click here\n(https://www.globenewswire.com/Tracker?data=LHf93P1ncZ4zgAoUqrcmZWhxCF36wysGLk7Y1qTEP6iJQ0MdhqMRsEtM4F-hwJoCPk6QDLz4jIoyEg2Ja69FWkKg7vMYoSb449l6mAGqqOaHcLcHBrxhCFsuep-7HiY1).\n\nAbout Tourette Syndrome \nTourette syndrome is a chronic neuro-developmental disorder characterized by\ninvoluntary motor and vocal tics beginning in childhood, often between 5 and\n10 years of age.(3) For people living with Tourette syndrome, symptoms can be\nfrequent, visible and disruptive, affecting everyday life.(3)\n\nAbout Ecopipam and Its Clinical Program \nEcopipam is a first-in-class investigational therapy designed to block\ndopamine signaling at the D1 receptor. D1 receptor hypersensitivity may\ncontribute to repetitive and compulsive behaviors associated with Tourette\nsyndrome. \n\nEcopipam was granted Priority Review by the FDA with Orphan Drug designation\nfor the treatment of pediatric patients with Tourette syndrome. Orphan Drug\ndesignation is reserved for patient populations of 200,000 or fewer. \n\nThe D1AMOND Phase 2b Trial was a 12-week randomized, double-blind,\nplacebo-controlled trial that studied 153 pediatric participants across 68\nsites in North America and Europe. The primary efficacy endpoint was the\nchange in the YGTSS-TTS, i.e., sum of the motor and vocal tic scores, from\nbaseline to end of therapy.(4) The associated Phase 2b open-label extension\nenrolled 121 pediatric subjects from the Phase 2b trial and followed them for\nup to 12 months’ duration to evaluate the long-term safety and tolerability\nof ecopipam.(5) The subsequent D1AMOND Phase 3 Trial was a double-blind,\nplacebo-controlled, randomized withdrawal trial enrolling a total of 216\npediatric and adult participants into an open-label stabilization period and\nrandomizing 104 participants (90 pediatric, 14 adult) across 77 sites in North\nAmerica and Europe. The objective of this study was to evaluate the\nmaintenance of efficacy of ecopipam in pediatric and adult responders\nutilizing the YGTSS-TTS change from randomization or increased\nTourette-specific care to determine relapse.(6) While this Phase 3 trial\nincluded adult participants, the accepted NDA and resulting indication sought\nby Teva are exclusively for pediatric patients. \n\nAbout Teva\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com. \n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, which are based on\nmanagement’s current beliefs and expectations and are subject to substantial\nrisks and uncertainties, both known and unknown, that could cause Teva’s\nfuture results, performance or achievements to differ significantly from that\nexpressed or implied by such forward-looking statements. All statements other\nthan statements of historical fact are, or may be deemed to be,\nforward-looking statements. In some cases, you can identify these\nforward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “developing,” “target,” “may,”\n“expand,” “intend,” “plan,” “believe” and other words and\nterms of similar meaning and expression in connection with any discussion of\nfuture performance. Important factors that could cause or contribute to such\ndifferences include risks and uncertainties relating to: our ability to\nsuccessfully develop, obtain regulatory approval for and commercialize\necopipam; our ability to successfully compete in the marketplace including our\nability to develop and commercialize ecopipam for the treatment of pediatric\npatients with Tourette syndrome; our ability to successfully execute on our\nPivot to Growth strategy, including to expand our innovative and biosimilar\nmedicines pipeline and to profitably commercialize our innovative medicines\nand biosimilar portfolio, whether organically or through business development,\nand to execute on our organizational transformation and to achieve expected\ncost savings; our significant indebtedness, which may limit our ability to\nincur additional indebtedness, engage in additional transactions or make new\ninvestments; and other factors discussed in this press release, in our\nQuarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual\nReport on Form 10-K for the year ended December 31, 2025, including in the\nsections captioned “Risk Factors” and “Cautionary Note Regarding Forward\nLooking Statements.” Forward-looking statements speak only as of the date on\nwhich they are made, and we assume no obligation to update or revise any\nforward-looking statements or other information contained herein, whether as a\nresult of new information, future events or otherwise. You are cautioned not\nto put undue reliance on these forward-looking statements.\n\nReferences:\n1. Karkanias, G. B., Flatt, J. A., Korb, R. T., Munschauer, F. E., Wanaski, S.\nP., Cunniff, T. M., & Gilbert, D. L. (2026). Targeting Dopamine Pathways for\nthe Treatment of Tourette Syndrome. Journal of Child Neurology.\nhttps://doi.org/10.1177/08830738261491159\n2. U.S. Food and Drug Administration (FDA) Approval Records: Haloperidol\n(1969), Pimozide (1984), Aripiprazole (2014); Pringsheim, T., et al. (2019).\nThe pharmacological management of tic disorders: an updated practice\nguideline. Neurology. \n3. CDC | Tourette Syndrome | Data and Statistics on Tourette Syndrome, 2024;\nMayo Clinic | Tourette Syndrome – Diagnosis and treatment, 2025. \n4. Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A\nRandomized Trial. Pediatrics. 2023;151(2):e2022059574.\ndoi:10.1542/peds.2022-059574 \n5. Gilbert DL, Kim DJB, Miller MM, et al. Safety and Effect of 12-Month\nEcopipam Treatment in Pediatric Patients with Tourette Syndrome. Mov Disord\nClin Pract. 2025;12(8):1157-1166. doi:10.1002/mdc3.70091. \n6. Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and Safety of Ecopipam\nfor Tourette Syndrome: A Phase 3 Randomized Clinical Trial. JAMA Neurol.\n2026;83(7):645–653. doi:10.1001/jamaneurol.2026.1431\nTeva Media Inquiries:\ntevacommunicationsnorthamerica@tevapharm.com\n\nTeva Investor Relations Inquiries:\nTevaIR@tevapharm.com","article_body_html":"","raw_payload":{"data":{"id":"nGNEb8dFgf-20261002","title":"Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients","author":"Globe Newswire","ticker":"TEVA","created":"2026-10-02T12:00:00.132Z","tickers":["TEVA"],"exchange":"","article_body":"* The published review examines dopamine’s role in tic generation and how\napproved and investigational drugs may affect dopamine to reduce tics as well\nas synthesizes clinical trial evidence that ecopipam reduces tic severity,\nprovides sustained benefit over time and helps prevent relapse without some of\nthe complications associated with antipsychotic agents.¹\n* Ecopipam is an investigational, selective D1 (dopamine) receptor antagonist\ntargeting dopaminergic signaling in the brain’s direct motor pathway\nimplicated in Tourette syndrome.\n* Unlike D2 antipsychotics that target D2 receptors in the indirect pathway,\necopipam selectively targets D1 receptors in the direct motor pathway,\noffering a differentiated approach that may reduce tic severity while\npotentially avoiding common adverse events associated with D2-targeting\ntherapies.(1)\nPARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a\nU.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),\ntoday announced that the Journal of Child Neurology published a comprehensive\nreview examining dopamine pathways in Tourette syndrome and the therapeutic\npotential of ecopipam, a first-in-class investigational selective D1\n(dopamine) receptor antagonist for the treatment of pediatric patients with\nTourette syndrome.(1,2) The review evaluates current treatment limitations and\ndetails how selectively targeting D1 receptors in the brain’s direct motor\npathway may offer a differentiated, non-antipsychotic approach for managing\ntics in pediatric patients.(1)\n\n“Tourette syndrome affects up to 1 in 130 children globally and can have a\nprofound impact on a child's daily life, education and social development,”\nsaid Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief\nMedical Officer at Teva. “The review published in the Journal of Child\nNeurology reinforces the potential of ecopipam’s selective dopamine D1\nreceptor approach. This is the kind of innovative programs we are pursuing at\nTeva—advancing differentiated science to address meaningful unmet needs.”\n\nThe comprehensive review details the neurobiological rationale for D1 receptor\nantagonism compared with existing therapies. In Tourette syndrome, elevated\ndopaminergic activity in the basal ganglia is proposed to contribute to the\nexpression of involuntary tics. Because D1 receptors are primarily expressed\nby neurons in the direct motor pathway, ecopipam is hypothesized to block\nexcess dopaminergic activity in this pathway, thereby normalizing downstream\nbasal ganglia signaling and movement patterns. In contrast, traditional\nantipsychotics target D2 receptors, which are primarily associated with the\nindirect pathway.\n\nThis mechanistic distinction is supported by clinical data synthesized across\nthe ecopipam development program. In a Phase 3 trial (n=216, including 167\npediatric), continued ecopipam treatment cut the risk of tic relapse by 50%\nversus placebo in pediatric participants (HR: 0.5; P=0.008), building on Phase\n2b and 12-month open-label data showing sustained reductions in tic severity.\nAcross clinical trials, the most common adverse events included somnolence,\nheadache, insomnia, fatigue and anxiety while ecopipam was not associated with\nclinically relevant weight gain, adverse metabolic effects or drug-induced\nmovement disorders. The potential importance of this efficacy and tolerability\nprofile is underscored by real-world treatment persistence data, which show\nthat treatment discontinuation rates among patients newly treated with D2\nreceptor antagonists were 61.2% by 3 months and 82.1% by 18 months.(1)\n\n“Treatment of Tourette syndrome can be complex, as clinicians must balance\ntic improvement with the side effect profiles of current therapies,” said\nDonald L. Gilbert, M.D., M.S., senior author of the review and Pediatric\nMovement Disorders and Tourette Syndrome Specialist, Division of Neurology,\nCincinnati Children’s Hospital Medical Center. “Ecopipam selectively\ntargets the dopamine D1 receptor, and the data reviewed in this publication\n– demonstrating reduced tic severity and sustained benefit without\nsignificant weight gain, metabolic complications or movement disorders –\nsupports continued research into D1 receptor antagonism for Tourette\nsyndrome.”\n\nFor more information on the review published online in the Journal of Child\nNeurology, click here\n(https://www.globenewswire.com/Tracker?data=LHf93P1ncZ4zgAoUqrcmZWhxCF36wysGLk7Y1qTEP6iJQ0MdhqMRsEtM4F-hwJoCPk6QDLz4jIoyEg2Ja69FWkKg7vMYoSb449l6mAGqqOaHcLcHBrxhCFsuep-7HiY1).\n\nAbout Tourette Syndrome \nTourette syndrome is a chronic neuro-developmental disorder characterized by\ninvoluntary motor and vocal tics beginning in childhood, often between 5 and\n10 years of age.(3) For people living with Tourette syndrome, symptoms can be\nfrequent, visible and disruptive, affecting everyday life.(3)\n\nAbout Ecopipam and Its Clinical Program \nEcopipam is a first-in-class investigational therapy designed to block\ndopamine signaling at the D1 receptor. D1 receptor hypersensitivity may\ncontribute to repetitive and compulsive behaviors associated with Tourette\nsyndrome. \n\nEcopipam was granted Priority Review by the FDA with Orphan Drug designation\nfor the treatment of pediatric patients with Tourette syndrome. Orphan Drug\ndesignation is reserved for patient populations of 200,000 or fewer. \n\nThe D1AMOND Phase 2b Trial was a 12-week randomized, double-blind,\nplacebo-controlled trial that studied 153 pediatric participants across 68\nsites in North America and Europe. The primary efficacy endpoint was the\nchange in the YGTSS-TTS, i.e., sum of the motor and vocal tic scores, from\nbaseline to end of therapy.(4) The associated Phase 2b open-label extension\nenrolled 121 pediatric subjects from the Phase 2b trial and followed them for\nup to 12 months’ duration to evaluate the long-term safety and tolerability\nof ecopipam.(5) The subsequent D1AMOND Phase 3 Trial was a double-blind,\nplacebo-controlled, randomized withdrawal trial enrolling a total of 216\npediatric and adult participants into an open-label stabilization period and\nrandomizing 104 participants (90 pediatric, 14 adult) across 77 sites in North\nAmerica and Europe. The objective of this study was to evaluate the\nmaintenance of efficacy of ecopipam in pediatric and adult responders\nutilizing the YGTSS-TTS change from randomization or increased\nTourette-specific care to determine relapse.(6) While this Phase 3 trial\nincluded adult participants, the accepted NDA and resulting indication sought\nby Teva are exclusively for pediatric patients. \n\nAbout Teva\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com. \n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, which are based on\nmanagement’s current beliefs and expectations and are subject to substantial\nrisks and uncertainties, both known and unknown, that could cause Teva’s\nfuture results, performance or achievements to differ significantly from that\nexpressed or implied by such forward-looking statements. All statements other\nthan statements of historical fact are, or may be deemed to be,\nforward-looking statements. In some cases, you can identify these\nforward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “developing,” “target,” “may,”\n“expand,” “intend,” “plan,” “believe” and other words and\nterms of similar meaning and expression in connection with any discussion of\nfuture performance. Important factors that could cause or contribute to such\ndifferences include risks and uncertainties relating to: our ability to\nsuccessfully develop, obtain regulatory approval for and commercialize\necopipam; our ability to successfully compete in the marketplace including our\nability to develop and commercialize ecopipam for the treatment of pediatric\npatients with Tourette syndrome; our ability to successfully execute on our\nPivot to Growth strategy, including to expand our innovative and biosimilar\nmedicines pipeline and to profitably commercialize our innovative medicines\nand biosimilar portfolio, whether organically or through business development,\nand to execute on our organizational transformation and to achieve expected\ncost savings; our significant indebtedness, which may limit our ability to\nincur additional indebtedness, engage in additional transactions or make new\ninvestments; and other factors discussed in this press release, in our\nQuarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual\nReport on Form 10-K for the year ended December 31, 2025, including in the\nsections captioned “Risk Factors” and “Cautionary Note Regarding Forward\nLooking Statements.” Forward-looking statements speak only as of the date on\nwhich they are made, and we assume no obligation to update or revise any\nforward-looking statements or other information contained herein, whether as a\nresult of new information, future events or otherwise. You are cautioned not\nto put undue reliance on these forward-looking statements.\n\nReferences:\n1. Karkanias, G. B., Flatt, J. A., Korb, R. T., Munschauer, F. E., Wanaski, S.\nP., Cunniff, T. M., & Gilbert, D. L. (2026). Targeting Dopamine Pathways for\nthe Treatment of Tourette Syndrome. Journal of Child Neurology.\nhttps://doi.org/10.1177/08830738261491159\n2. U.S. Food and Drug Administration (FDA) Approval Records: Haloperidol\n(1969), Pimozide (1984), Aripiprazole (2014); Pringsheim, T., et al. (2019).\nThe pharmacological management of tic disorders: an updated practice\nguideline. Neurology. \n3. CDC | Tourette Syndrome | Data and Statistics on Tourette Syndrome, 2024;\nMayo Clinic | Tourette Syndrome – Diagnosis and treatment, 2025. \n4. Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A\nRandomized Trial. Pediatrics. 2023;151(2):e2022059574.\ndoi:10.1542/peds.2022-059574 \n5. Gilbert DL, Kim DJB, Miller MM, et al. Safety and Effect of 12-Month\nEcopipam Treatment in Pediatric Patients with Tourette Syndrome. Mov Disord\nClin Pract. 2025;12(8):1157-1166. doi:10.1002/mdc3.70091. \n6. Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and Safety of Ecopipam\nfor Tourette Syndrome: A Phase 3 Randomized Clinical Trial. JAMA Neurol.\n2026;83(7):645–653. doi:10.1001/jamaneurol.2026.1431\nTeva Media Inquiries:\ntevacommunicationsnorthamerica@tevapharm.com\n\nTeva Investor Relations Inquiries:\nTevaIR@tevapharm.com"},"type":"article","timestamp":"2026-10-02T12:00:00.459759898Z","server_sent_at_ms":1790942400459},"received_at":"2026-10-02T12:00:00.549Z","source_url":null},"analysis":{"id":"147925","press_release_id":"159305","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Teva announced that the Journal of Child Neurology published a comprehensive review of dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, Teva's first-in-class selective D1 receptor antagonist for pediatric patients.\n\nThe review synthesizes Phase 3 data (n=216) showing continued ecopipam treatment cut pediatric tic-relapse risk by 50% versus placebo (HR: 0.5; P=0.008), without clinically relevant weight gain, metabolic effects, or drug-induced movement disorders.\n\nEcopipam's NDA has been accepted with FDA Priority Review and Orphan Drug designation; the publication is supportive scientific groundwork rather than a new regulatory milestone.\n\nReal-world persistence data highlighted in the release show 61.2% discontinuation of D2 antipsychotics by 3 months, underscoring the unmet need ecopipam targets.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Scientific groundwork for ecopipam's pediatric Tourette NDA ahead of a Priority Review decision -- keep on the watchlist."},"keyFigures":{"drugName":"ecopipam","phaseOfTrial":"Phase 3","customDimensions":{"phase3_n":216,"phase3_pediatric_n":167,"tourette_prevalence":"up to 1 in 130 children globally","d2_discontinuation_3mo":"61.2%","phase3_relapse_p_value":"P=0.008","d2_discontinuation_18mo":"82.1%","phase3_relapse_hazard_ratio":"HR: 0.5"}},"quotedText":"Ecopipam selectively targets the dopamine D1 receptor, and the data reviewed in this publication – demonstrating reduced tic severity and sustained benefit without significant weight gain, metabolic complications or movement disorders – supports continued research into D1 receptor antagonism for Tourette syndrome.","namedEntities":{"people":[{"name":"Eric Hughes, M.D., Ph.D.","role":"EVP Global R&D and Chief Medical Officer, Teva"},{"name":"Donald L. Gilbert, M.D., M.S.","role":"senior author of the review; Pediatric Movement Disorders Specialist, Cincinnati Children's Hospital Medical Center"}],"products":["ecopipam"],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA","relationship":"filer"},{"name":"Cincinnati Children's Hospital Medical Center","relationship":"academic/clinical partner of lead author"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Journal publication synthesizing existing ecopipam Phase 2b/3 data is a supportive but non-binary event; NDA is already accepted with FDA Priority Review. No new data or regulatory decision announced."},"tickerRelevance":{"others":[],"primary":"TEVA"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"marketSize":"orphan indication (<200k patients)","tickerTier":"large-cap pharma","eventGravity":"supportive publication, no new data or regulatory action","drugProgramStage":"NDA accepted, Priority Review pending"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Teva announced that the Journal of Child Neurology published a comprehensive review of dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, Teva's first-in-class selective D1 receptor antagonist for pediatric patients.\n\nThe review synthesizes Phase 3 data (n=216) showing continued ecopipam treatment cut pediatric tic-relapse risk by 50% versus placebo (HR: 0.5; P=0.008), without clinically relevant weight gain, metabolic effects, or drug-induced movement disorders.\n\nEcopipam's NDA has been accepted with FDA Priority Review and Orphan Drug designation; the publication is supportive scientific groundwork rather than a new regulatory milestone.\n\nReal-world persistence data highlighted in the release show 61.2% discontinuation of D2 antipsychotics by 3 months, underscoring the unmet need ecopipam targets.","key_figures":{"drugName":"ecopipam","phaseOfTrial":"Phase 3","customDimensions":{"phase3_n":216,"phase3_pediatric_n":167,"tourette_prevalence":"up to 1 in 130 children globally","d2_discontinuation_3mo":"61.2%","phase3_relapse_p_value":"P=0.008","d2_discontinuation_18mo":"82.1%","phase3_relapse_hazard_ratio":"HR: 0.5"}},"named_entities":{"people":[{"name":"Eric Hughes, M.D., Ph.D.","role":"EVP Global R&D and Chief Medical Officer, Teva"},{"name":"Donald L. Gilbert, M.D., M.S.","role":"senior author of the review; Pediatric Movement Disorders Specialist, Cincinnati Children's Hospital Medical Center"}],"products":["ecopipam"],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA","relationship":"filer"},{"name":"Cincinnati Children's Hospital Medical Center","relationship":"academic/clinical partner of lead author"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T12:00:07.321Z","global_importance":25,"audience_relevance":25,"importance_components":{"marketSize":"orphan indication (<200k patients)","tickerTier":"large-cap pharma","eventGravity":"supportive publication, no new data or regulatory action","drugProgramStage":"NDA accepted, Priority Review pending"}},"durationMs":6722,"modelName":"glm-5.3-flashx"}}